The firm pointed to the extensive gross-to-net adjustments that the manufacturers are already providing on these drugs. BMO Capital Markets, for its part, wrote in a note to investors, We reiterate that the important comparison remains the difference between the products newly discounted price and the products ultimate net price, including rebates, instead of their list prices
Many users are left to pay for GLP-1 weight loss medications, which can cost more than $1,000 per month, out of pocket
Atkins WM: Non-michaelis-Menten kinetics in cytochrome P450-catalyzed reactions
This gives people a new option for managing their weight under medical supervision
As research into GLP1 receptor agonists accelerates, leveraging cutting-edge fluorescent assay platforms is pivotal for producing robust, actionable pharmacological data